Otilia Dumitrescu

Patients with chemotherapy‐refractory mantle cell lymphoma experience high response rates and identical progression‐free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre phase 2 clinical trial

Owen A. O’Connor, Craig H. Moskowitz, Carol S. Portlock et al. · British Journal of Haematology · 2009 · 83 citations · Full text

Pathology, Single Agent Bortezomib, Pharmacotherapy +17

Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma

John F. Gerecitano, Carol S. Portlock, Craig H. Moskowitz et al. · British Journal of Haematology · 2009 · 48 citations · Full text

Time to Treatment Response in Patients with Follicular Lymphoma Treated with Bortezomib Is Longer Compared with Other Histologic Subtypes

Owen A. O’Connor, Carol S. Portlock, Craig H. Moskowitz et al. · Clinical Cancer Research · 2010 · 44 citations

Phase I Trial of Weekly and Twice-Weekly Bortezomib with Rituximab, Cyclophosphamide, and Prednisone in Relapsed or Refractory Non–Hodgkin Lymphoma

John F. Gerecitano, Carol S. Portlock, Paul A. Hamlin et al. · Clinical Cancer Research · 2011 · 27 citations · Full text

Early Safety and Efficacy Analysis of a Phase II Study of Sequential R-CHOP and Yttrium-90 Ibritumomab Tiuxetan (Zevalin®) for Elderly High Risk Patients with Untreated DLBCL.

Paul A. Hamlin, Craig H. Moskowitz, Brett Wegner et al. · Blood · 2005 · 22 citations